Veru Inc. (NASDAQ:VERU) Q1 2024 Earnings Conference Call May 8, 2024 8:00 AM ET

Company Participants

Sam Fisch - Investor Relations & Corporate Communications
Mitchell Steiner - Chief Executive Officer
Michele Greco - Chief Financial Officer
Gary Barnette - Chief Scientific Officer

Conference Call Participants

Dennis Ding - Jefferies
William Wood - B. Riley Securities
Rohan Mathur - Oppenheimer

Operator

Good morning ladies and gentlemen and welcome to Veru Inc.'s Investors Conference Call. [Operator Instructions] Please note that this event is being recorded.

I would now like to turn the conference over to Mr. Sam Fisch, Veru Inc.'s Executive Director, Investor Relations and Corporate Communications. Please go ahead.

Sam Fisch

The statements made on this conference call may be forward-looking statements. Forward-looking statements may include but are not necessarily limited to, statements of the company's plans, objectives, expectations or intentions regarding its business, operations, regulatory interactions, finances and development and product portfolio. Such forward-looking statements are subject to known and unknown risks and uncertainties and our actual results may differ significantly from those projected, suggested or included in any forward-looking statements. Risks that may cause actual results or developments to differ materially are contained in our 10-Q and 10-K SEC filings, as well as in our press releases from time to time.

I would now like to turn the conference call over to Dr. Mitchell Steiner, Veru Inc.'s, Chairman, CEO and President.

Mitchell Steiner

Good morning. With me on this morning's call are Dr. Gary Barnette, the Chief Scientific Officer; Michele Greco, Chief Financial Officer and Chief Administrative Officer; Michael Purvis, Executive Vice President, General Counsel and Corporate Strategy. And Sam Fisch, the Executive Director of Investor Relations and Corporate Communications.

Thank you for joining our Q2 fiscal year 2024 earnings call. Veru is a late clinical stage biopharmaceutical company focused on developing innovative medicines for high quality weight loss, oncology and acute respiratory distress syndrome. The company's drug development pipeline includes 2 late-stage novel oral small molecules, enobosarm and sabizabulin.

In our weight loss pipeline, we have enobosarm, also known as ostarine, MK-2866, GTx-024 and VERU-024 which is an oral selective androgen receptor modulator, SARM. And enobosarm is being developed as a treatment in combination with glucagon-like peptide-1 receptor agonist which I'll be referring to as GLP-1 receptor agonist which is a weight loss drug to augment fat loss and to avoid muscle loss in overweight or obese patients for chronic weight management.